• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice.

作者信息

Mylonas E, Janin M, Bawa O, Opolon P, David M, Quivoron C, Bernard O A, Ottolenghi C, DeBotton S, Penard-Lacronique V

机构信息

1] Institut National de la Santé et de la Recherche Médicale (INSERM) U985, Institut Gustave Roussy, Villejuif, France [2] Université Paris Sud-11, Orsay, France.

1] Biochimie métabolique, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Necker-Enfants Malades, Paris, France [2] INSERM U747, Université Paris Descartes, Paris, France.

出版信息

Leukemia. 2014 Jun;28(6):1343-6. doi: 10.1038/leu.2014.18. Epub 2014 Jan 14.

DOI:10.1038/leu.2014.18
PMID:24418992
Abstract
摘要

相似文献

1
Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice.异柠檬酸脱氢酶（IDH）2 R140Q突变可诱导小鼠发生髓系和淋巴系肿瘤。
Leukemia. 2014 Jun;28(6):1343-6. doi: 10.1038/leu.2014.18. Epub 2014 Jan 14.
2
Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.异柠檬酸脱氢酶2突变的母细胞样浆细胞样树突状细胞肿瘤中血浆d-2-羟基戊二酸水平升高。
Hum Pathol. 2015 Feb;46(2):322-6. doi: 10.1016/j.humpath.2014.10.013. Epub 2014 Nov 4.
3
IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis.IDH1 突变通过扰乱血红素生物合成和红细胞生成导致小鼠骨髓增生异常。
Blood. 2021 Feb 18;137(7):945-958. doi: 10.1182/blood.2020007075.
4
Normal myeloid progenitor cell subset-associated gene signatures for acute myeloid leukaemia subtyping with prognostic impact.与正常髓系祖细胞亚群相关的基因特征可用于急性髓系白血病亚类分型，并具有预后影响。
PLoS One. 2020 Apr 23;15(4):e0229593. doi: 10.1371/journal.pone.0229593. eCollection 2020.
5
Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.非 del(5q) 骨髓增生异常综合征中造血干细胞/祖细胞的结构和功能异质性。
Blood. 2017 Jan 26;129(4):484-496. doi: 10.1182/blood-2016-03-707745. Epub 2016 Nov 16.
6
TET2 Loss Dysregulates the Behavior of Bone Marrow Mesenchymal Stromal Cells and Accelerates Tet2-Driven Myeloid Malignancy Progression.TET2 缺失失调骨髓间充质基质细胞的行为并加速 Tet2 驱动的髓系恶性肿瘤进展。
Stem Cell Reports. 2018 Jan 9;10(1):166-179. doi: 10.1016/j.stemcr.2017.11.019. Epub 2017 Dec 28.
7
A lymphoblast model for IDH2 gain-of-function activity in d-2-hydroxyglutaric aciduria type II: novel avenues for biochemical and therapeutic studies.II型d-2-羟基戊二酸尿症中IDH2功能获得性活性的淋巴母细胞模型：生物化学和治疗研究的新途径。
Biochim Biophys Acta. 2011 Nov;1812(11):1380-4. doi: 10.1016/j.bbadis.2011.08.006. Epub 2011 Aug 24.
8
A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy.一种小鼠Mll-AF4基因敲入模型导致淋巴和髓系失调以及血液系统恶性肿瘤。
Blood. 2006 Jul 15;108(2):669-77. doi: 10.1182/blood-2005-08-3498. Epub 2006 Mar 21.
9
Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.突变型异柠檬酸脱氢酶2（IDH2）在白血病起始和维持中的原癌基因作用
Cell Stem Cell. 2014 Mar 6;14(3):329-41. doi: 10.1016/j.stem.2013.12.016. Epub 2014 Jan 16.
10
Sequential B-lymphoid and myeloid blastic transformation of Philadelphia chromosome-negative myeloproliferative neoplasm.费城染色体阴性骨髓增殖性肿瘤的序贯B淋巴细胞和髓细胞母细胞转化
Br J Haematol. 2019 Jan;184(1):8. doi: 10.1111/bjh.15663. Epub 2018 Nov 8.

引用本文的文献

1
Improving prediction accuracy in acute myeloid leukaemia: micro-environment, immune and metabolic models.提高急性髓系白血病的预测准确性：微环境、免疫和代谢模型
Leukemia. 2021 Nov;35(11):3073-3077. doi: 10.1038/s41375-021-01377-0. Epub 2021 Aug 7.
2
NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.基于 NGS 的液体活检分析鉴定出对 ALK 抑制剂耐药的机制：迈向个体化 NSCLC 治疗的一步。
Mol Oncol. 2021 Sep;15(9):2363-2376. doi: 10.1002/1878-0261.13033. Epub 2021 Jun 18.
3
Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors.

本文引用的文献

1
Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.IDH1 和 IDH2 突变的初发急性髓系白血病中的血清 2-羟戊二酸产生：急性白血病法国协会组的一项研究。
J Clin Oncol. 2014 Feb 1;32(4):297-305. doi: 10.1200/JCO.2013.50.2047. Epub 2013 Dec 16.
2
Induction of sarcomas by mutant IDH2.突变 IDH2 诱导肉瘤。
Genes Dev. 2013 Sep 15;27(18):1986-98. doi: 10.1101/gad.226753.113.
3
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.
突变使急性髓系白血病对 PARP 抑制剂敏感，而 IDH1/2 突变抑制剂可逆转这种敏感性。
Clin Cancer Res. 2018 Apr 1;24(7):1705-1715. doi: 10.1158/1078-0432.CCR-17-2796. Epub 2018 Jan 16.
4
Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism.源自乳腺和前列腺的肿瘤起始细胞在与铁代谢相关的基因表达上出现改变。
Oncotarget. 2017 Jan 24;8(4):6376-6398. doi: 10.18632/oncotarget.14093.
5
A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model.突变型异柠檬酸脱氢酶2的小分子抑制剂可挽救II型D-2-羟基戊二酸尿症小鼠模型中的心肌病。
J Inherit Metab Dis. 2016 Nov;39(6):807-820. doi: 10.1007/s10545-016-9960-y. Epub 2016 Jul 28.
6
Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation.突变型异柠檬酸脱氢酶：连接代谢、表观遗传学和转录调控的白血病表型的可靶向驱动因子。
Epigenomics. 2016 Jul;8(7):945-57. doi: 10.2217/epi-2016-0008. Epub 2016 Jul 19.
7
Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.分子途径：癌症中的异柠檬酸脱氢酶突变
Clin Cancer Res. 2016 Apr 15;22(8):1837-42. doi: 10.1158/1078-0432.CCR-13-1333. Epub 2016 Jan 27.
8
Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms.骨髓肿瘤中始祖型和非始祖型异柠檬酸脱氢酶1和异柠檬酸脱氢酶2突变的临床及生物学意义
Leukemia. 2015 Nov;29(11):2134-42. doi: 10.1038/leu.2015.91. Epub 2015 Apr 3.
9
[Isocitrate dehydrogenase mutation in acute myeloid leukemia].急性髓系白血病中的异柠檬酸脱氢酶突变
Zhonghua Xue Ye Xue Za Zhi. 2015 Jan;36(1):82-4. doi: 10.3760/cma.j.issn.0253-2727.2015.01.023.
10
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.来自中药的潜在线粒体异柠檬酸脱氢酶R140Q突变体抑制剂对癌症的作用
Biomed Res Int. 2014;2014:364625. doi: 10.1155/2014/364625. Epub 2014 Jun 5.
癌症相关 IDH2 突变驱动急性髓系白血病，对 Brd4 抑制敏感。
Genes Dev. 2013 Sep 15;27(18):1974-85. doi: 10.1101/gad.226613.113.
4
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.突变型 IDH1 在体内促进白血病发生，并且可以在人急性髓系白血病中被特异性靶向。
Blood. 2013 Oct 17;122(16):2877-87. doi: 10.1182/blood-2013-03-491571. Epub 2013 Aug 16.
5
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.血清 2-羟戊二酸水平可预测急性髓系白血病中异柠檬酸脱氢酶突变和临床结局。
Blood. 2013 Jun 13;121(24):4917-24. doi: 10.1182/blood-2013-03-493197. Epub 2013 May 2.
6
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.羟基的差异有多大：突变 IDH、（R）-2-羟基戊二酸和癌症。
Genes Dev. 2013 Apr 15;27(8):836-52. doi: 10.1101/gad.217406.113.
7
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.靶向抑制白血病细胞中的突变 IDH2 诱导细胞分化。
Science. 2013 May 3;340(6132):622-6. doi: 10.1126/science.1234769. Epub 2013 Apr 4.
8
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.一种突变 IDH1 抑制剂可延缓神经胶质瘤细胞的生长并促进其分化。
Science. 2013 May 3;340(6132):626-30. doi: 10.1126/science.1236062. Epub 2013 Apr 4.
9
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.(R)-2-羟基戊二酸足以促进白血病发生，其作用是可逆的。
Science. 2013 Mar 29;339(6127):1621-5. doi: 10.1126/science.1231677. Epub 2013 Feb 7.
10
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.IDH1(R132H) 突变增加了小鼠造血祖细胞并改变了表观遗传学。
Nature. 2012 Aug 30;488(7413):656-9. doi: 10.1038/nature11323.